We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
New CEO joined on 1st June - many seem to like c3 months to get their feet under the table and a first 100 days update is quite common. This would tally with H1 numbers which are usually reported in mid Sept.
However, with the US launch starting 4 weeks ago i am sure he will want to provide an update prior to this, if possible. Clearly any significant trend data will take a few months to be meaningful but details regarding 1st revenues and if progress is in line with management expectations etc would be nice. Maybe mid August?
Regarding China - a frustrating one here but it needs to go through the regulatory approval process again as the Chinese felt the existing data did not contain sufficient Chinese/Asian patients to be meaningful.
Essentially it appears phase 3 is being repeated with Chinese patients. Results should be the same but it does take time. I suspect study will take up to 1 year and then the Chinese FDA equivalent will need to review results etc, hence the 2023 date for selling feraccru. ASK the Chinese company are paying for this study so there is no costs for STX (other than to supply the product).
Noticed STX OTC price ticked up by c10% in US (albeit on very low volumes) so maybe there is some interest starting to build over there.
Patients as always is required here. All the building blocks are now in place
Until proven otherwise the trading range is 30p-60p.
I am bullish, but I cannot tell or anyone else, if it is going to breakdown or breakout.
If all goes to plan and sales take off,great, but the US market is difficult to gain a foothold in and traders should expect a rocky ride,when has stx management delivered according to plan ?
I would add on a breakout above 70p with volume.
Stay long but patient and keep expectations real,the upside should take care of itself but it is out of our control.
Thanks for the welcome Shandypants - appreciated.
Understood that the 'disappointingly discounted placing' must have been a real pain for all longer term holders but tbh that's what had attracted me to the stock in the first place and I built up my position shortly after from about 34p ending up with an average price of around 41.5. Might not have been in at all otherwise.
Thanks too for your views on where you anticipate the share price going. I guess until the time we get some initial firm news on US sales the share price is open to being a bit of a lottery. Once something is declared (which trust will live up to the billing) there will be no end of calculations and predictions which will hopefully catch the imagination of many more investors and thus boost the share price to more reasonable levels.
I must say I had expected a bit more profile and maybe comment on overall operations from our new CEO after 2 months in place. As someone has said previously it would be good to see STX get a better handle on the UK / European ventures for instance. Maybe the new broom is doing a bit more sweeping behind the scenes than we give credit for.
On the subject of non US areas of involvement does anyone know why the China contract needs to take so long to play out?
Hopefully with everyone gradually pulling through Covid the newsflow including from US will be much improved. Patience is indeed a virtue.
The future prospects for STX remain very exciting.
apropos - welcome.
IMHO i think the recent fall has just created a massive value gap so this is now slowly being filled, hence the SP tick up.
For me there are a couple of big price points for STX. One is at 60p (100% increase on discounted placing price) and the other is 90p which is a c£200m valuation (where we were after FDA approval in 2019, with no US sales).
After the disappointing discounted placing which damaged the SP the price slowly rose back to 60p which clearly resulted in a few new shares being sold/ positions de-risked.
The recent 1/7/21 US announcement was encouraging as we have (just) managed to ensure the Q2 timescales did not slip. However, now the hard work begins so it is likely that STX need a few months to determine progress and trends etc. I suspect being AIM a few sold off with the intention of revisiting in a few months. Maybe a 20% drop e.g. 60p to 50p ish was expected. However, with market uncertainty the price has continued dropping to almost 40p.
So to get back to 60p (only a £130m valuation) we now need a near 50% rise. IMHO buying at these prices is a no brainer.
Any positive news will get this back to over 60p pretty quickly IMHO (and some may bank their 50% gain).
However, is say the end of year update (Jan or Feb 2022??) states we are ahead of schedule or exceeding expectations etc then the 90p will go quite quickly IMHO.
Just wondering what has prompted the buying interest today with back up to average volume and a few serious buys. Maybe a mention on a 'tip sheet' or in a magazine?
I for one am certainly happy to see some northward progress for once with it bouncing off almost exactly my averaged in price which I hadn't expected to revisit I must admit even though the arrival of further news is unknown. I am quite substantially invested here for my portfolio so some further progress will be most welcome!
A lot of buys showing on L2. Moving back up. Under valued at current market cap
Looks like the accumulation phase is coming to an end.
Hopefully heading to 65/70p in the non too distant.
Have a good day all :)
Can't buy any at moment..no stock